How to Get BPC-157 by Prescription
In a Federal Register notice filed October 28, 2026, HHS said it does not intend to take enforcement action against state-licensed pharmacies and physicians compounding BPC-157 and five other peptides. Here is what that changes, what it does not, and how the prescription route works.
What the HHS Policy Actually Says
HHS says it "does not intend to take enforcement action" against a State-licensed pharmacy, Federal facility, or licensed physician compounding with a peptide in Appendix A. The notice says compounded drugs are not FDA-approved and the policy "is not binding on HHS or the public."
The policy applies while the 503A bulks list is developed through rulemaking. FDA may later propose adding some or all six peptides to that list. HHS may revisit the policy if a safety signal or product-quality issue arises.
Published summaries of Appendix B describe conditions including a patient-specific prescription, one peptide per product, bulk powder from an FDA-registered manufacturer with a certificate of analysis, adverse-event reporting, required labeling, and an FDA 510(k)-cleared syringe as the only device.
The notice sets federal enforcement policy only. State boards of pharmacy still license and regulate compounding pharmacies, and some may keep their own limits. Check your state before you assume a pharmacy can fill it.
What the Data Shows
How to Get a BPC-157 Prescription Under the Policy
- Find a licensed prescriber. The policy covers compounding against a valid, patient-specific prescription. An in-person physician or a telehealth clinician licensed in your state can write it. Published summaries say the policy gives no dosing guidance, so the prescriber decides whether it fits you at all.
- Get a prescription written for you by name. Section 503A compounding is patient-specific. A clinic that sells vials with no prescription, or one prescription shared across a household, is outside the policy.
- Have it filled by a state-licensed 503A pharmacy. The HHS notice names State-licensed pharmacies, Federal facilities and licensed physicians. 503B outsourcing facilities are not covered, according to trade summaries of the policy appendix. Check the pharmacy's license on your state board's lookup (NABP directory of state boards) and confirm it can ship to your state.
- Ask the pharmacy four questions. Who manufactured the bulk BPC-157 powder, and is that site FDA-registered? Can you see the certificate of analysis? Is the product a single peptide (no BPC-157 plus TB-500 vials)? Which dosage form are they making? Trade coverage of Appendix B lists subcutaneous, intramuscular, oral and topical forms for BPC-157, with extra absorption documentation required for oral products.
- Get a written price before you pay. We found no published price list. Monthly figures quoted on X are anecdotes, not data.
- Report problems. Serious side effects and quality problems go to FDA MedWatch. HHS says it may revisit the policy if a safety signal or product-quality issue appears.
Pharmacy Prescription vs Research-Use Vials
Regulatory sources: the HHS Federal Register notice 2026-22192 (PDF), Docket HHS-OASH-2026-0496 on regulations.gov, the HHS policy appendix, and Lachman Consultants analysis (Oct 28, 2026). Route and condition details come from published summaries of the appendix; check the HHS document for the current text.
Key Takeaways
- HHS announced an interim enforcement discretion policy for six peptides, including BPC-157, in a Federal Register notice filed October 28, 2026 (Docket HHS-OASH-2026-0496).
- It covers State-licensed pharmacies, Federal facilities and licensed physicians compounding under section 503A, which requires a patient-specific prescription.
- HHS states the policy is not FDA approval, is not binding, and may be revisited if a safety or quality problem appears.
- A 2026 systematic review found three human BPC-157 studies with 30 participants in total, all rated poor quality with very low certainty of evidence.
- One of those pilots used BPC-157 made by a 503A compounding pharmacy: 10 of 12 women with interstitial cystitis reported complete symptom resolution, with no control group.
- Of the 503A pharmacies that received FDA compounding warning letters from 2017 to 2021, 79% had sterile-compounding environment problems and 64% had produced some products without valid patient-specific prescriptions.
- Whether FDA rulemaking will add BPC-157 to the 503A bulks list, and when.
- What a compounded BPC-157 prescription will cost. No price data has been published.
- Whether BPC-157 works for any human condition. No controlled human trial has been published.
- Long-term human safety. A 2025 systematic review found no clinical safety data.
- How each state board of pharmacy will treat the federal policy.
- What dose is appropriate. The policy leaves dosing to the prescriber, and no validated human dosing data exist.
Frequently Asked Questions
Is BPC-157 legal to get by prescription now?
HHS says it will not take enforcement action against state-licensed 503A pharmacies and physicians that compound BPC-157 on a patient-specific prescription and meet the policy conditions. That is enforcement discretion, not FDA approval. HHS calls it interim and non-binding, it can be revisited, and state pharmacy rules still apply. Source: Federal Register notice 2026-22192.
How do I get a BPC-157 prescription?
See a licensed prescriber, in person or by telehealth in your state, who agrees it is appropriate and writes a prescription in your name. A state-licensed 503A pharmacy then compounds it. Ask the pharmacy who made the bulk powder, whether that site is FDA-registered, and for the certificate of analysis before you pay.
How much does compounded BPC-157 cost?
Nobody has published reliable pricing yet. Figures circulating on social media are single anecdotes. Expect the cost to include the prescriber visit and the compounded product, and ask the pharmacy for a written quote covering the dosage form, quantity and shipping before you commit to anything.
Does the HHS policy cover research-use-only BPC-157?
No. The policy covers compounding by state-licensed pharmacies, Federal facilities and licensed physicians against a prescription. Vials sold as research chemicals "not for human use" sit outside it, and HHS described the policy as a way to discourage the widespread use of research-use-only peptides.
Which peptides does the HHS policy cover?
Six, listed in Appendix A: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. These match the six that the FDA Pharmacy Compounding Advisory Committee recommended in July 2026. DSIP was rejected by that committee and is not on the list. CJC-1295 and ipamorelin are not on it either.
Research-Use-Only BPC-157 (Not the Prescription Route)
This is not a prescription and not a state-licensed 503A pharmacy. Research-use-only vials are sold "not for human use" and sit outside the HHS policy described above. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).
View Research-Grade BPC-157 at Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
Related HighPeptides Research
Peer-Reviewed References
Reading a certificate of analysis, vendor evaluation, pricing, supplies and storage. No dosing schedules, no protocols.
The Peptide Buyer’s Playbook ($19) All ebooks & guides →Educational purposes only. Not medical advice.
This page describes a federal enforcement policy, not legal advice. HHS calls the policy interim and non-binding, and state pharmacy law still applies. Check the current HHS text and your state board before acting.
Compounded drugs are not FDA-approved. Talk to a licensed clinician before starting any peptide.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.